The Revenue Rises
Trending Now
Stock Market News UK Update: FTSE 100 &...
Stock Market News UK Update: FTSE 100 &...
DP Trading Room: Key Support Levels for the...
Stock Market News UK Update: FTSE 100 &...
Stock Market News UK Update: FTSE 100 &...
Stock Market News UK Update: FTSE 100 &...
Stock Market News UK Update: FTSE 100 &...
Retirees ‘stunned’ as market turmoil over tariffs shrinks...
Week Ahead: NIFTY Set To Open Lower; Relative...
Market Drop Compared to 2020: What You Need...

The Revenue Rises

Stocks

Missed Amgen’s 5% Surge? Here’s What You Need to Know Now!

by admin February 6, 2025
February 6, 2025
Missed Amgen’s 5% Surge? Here’s What You Need to Know Now!

On Wednesday morning, the markets wavered, with cautious trading across the board, except for the Dow, which outpaced the S&P 500 and Nasdaq. Looking for stocks showing strength amid the uncertainty, I turned to the Market Movers tool on my Dashboard. What I found caught my attention.

FIGURE 1. MARKET MOVERS TOOL. AMGN, third from bottom, caught my attention, as the sector has been showing up on quite a few bullish StockCharts scans.Image source: StockCharts.com. For educational purposes.

The Health Care sector has been showing up on various scans over the past week, and Amgen, Inc. (AMGN) has been on my radar for quite some time due to several developments that I’ve been following.

To begin, I needed to get a wider perspective, so I switched to MarketCarpets and zoomed-in on the one-day performance of the Health Care sector.

FIGURE 2. MARKETCARPETS FOR THE HEALTHCARE SECTOR. Notice AMGN at the top of the list on the table to the right.Image source: StockCharts.com. For educational purposes.

Amgen’s stock surged over 5% (top of the table on the right) despite an FDA hold on its obesity drug trial, as strong Q4 earnings beat Wall Street’s expectations. On top of this, its sales for Repatha soared 45%, and its promising weight-loss drug MariTide is set for late-stage trials in mid-2025.

At this point, I wanted a clearer picture of how AMGN stacked up against its peers. I compared its performance to the biotech industry ($DJUSBT), the pharmaceutical sector ($DJUSPR), and the broader healthcare market (XLV) using PerfCharts. Here’s what I got:

FIGURE 3,. PERFCHARTS COMPARING THE HEALTH CARE SECTOR WITH BIOTECH AND PHARMA INDUSTRIES AND AMGEN. The one-year comparative lookback shows AMGN dragging significantly.Chart source: StockCharts.com. For educational purposes.

Over the past year, AMGN significantly underperformed both industries and the broader sector. So, does Wednesday’s rally indicate strong optimism on weak prospects, or does it present an undervalued opportunity with plenty of room to run?

Let’s take a longer-term view of AMGN’s price action and analyze its weekly chart.

FIGURE 4. WEEKLY CHART OF AMGN. Note how price respected the 100- and 200-period EMAs.Chart source: StockCharts.com. For educational purposes.

AMGN’s fluctuations over the last five years may have been volatile, but the underlying trend has been relatively steady and bullish. Notice how AMGN’s price respected the 100-period and 200-period exponential moving averages (EMAs). Also notice how this dynamic is captured by the Stochastic Oscillator, which reflects the upward bounces in its oversold range below the 20 level signaling renewed buying pressure. Based on the current reading, the indicator is barely reaching the 50-line, suggesting that if AMGN maintains its bullish momentum, it has plenty of room to run before it’s in overbought territory.

But things may look different on a daily scale, so let’s shift over to a daily chart.

FIGURE 5. DAILY CHART OF AMGN. Watch the support and resistance levels for entry and exit points.Chart source: StockCharts.com. For educational purposes.

Following a steep descent last November, AMGN found support the next month near $257.50, coinciding with its April 2024 low. That level was retested twice before the sharp rally that culminated in Wednesday’s price spike.

While the On Balance Volume (OBV) shows strong buying pressure fueling the surge, the Relative Strength Index (RSI) suggests the current swing is overbought. Considering the parabolic trajectory of the move, it’s likely that momentum will stall and price will eventually pull back in the next few sessions.

Key levels to watch:

Upside Resistance:

  • AMGN faces resistance at $310 and $327.50, which mark the lower and upper boundaries of its most recent consolidation range.

Downside Support:

  • If AMGN pulls back before breaking these resistance levels, the first key support to watch is $291, a level that held multiple times during May–June 2024, signaling strong buying interest.
  • The second level of support would be at $275, the November swing low.

If price falls below $275, the likelihood of a bullish reversal becomes uncertain, as this breakdown could signal weakening technical (and also fundamental) momentum.

At the Close

AMGN is another relatively expensive stock. If this is the case, then you might want to take a look at the OptionsPlay Strategy Center to find alternative strategies that better align with your capital resources and risk tolerance. AMGN’s recent rally, while impressive, raises important questions about its sustainability. You can use the tools mentioned above to find similar stocks if AMGN doesn’t interest you. If it does, however, the key levels discussed above should help guide you in your analysis.


Disclaimer: This blog is for educational purposes only and should not be construed as financial advice. The ideas and strategies should never be used without first assessing your own personal and financial situation, or without consulting a financial professional.

previous post
Quantum Computing Investments: Opportunities & Risks
next post
All Quiksilver, Billabong and Volcom stores to close in U.S.

Related Posts

What Higher Rates Could Mean for the S&P...

January 11, 2025

DP Trading Room: A Case for a Market...

October 8, 2024

Election Aftermath: Unleashing Profitable Small Cap Stocks

November 8, 2024

Investing in the Age of Tariffs: Safeguard Your...

January 29, 2025

Is a New Market Uptrend Starting? Key Signals...

March 16, 2025

What Does a Market Top Look Like?

July 20, 2024

Stealth AI Stocks Are Taking Off in a...

October 5, 2024

Plunge in Treasury Yields Triggers Gap-Surge in Home...

November 28, 2024

Why Bonds and Gold Are Outperforming Stocks

August 13, 2024

S&P 500 Dives After Failed Test of Price...

April 2, 2025

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Stock Market News UK Update: FTSE 100 & 250 Rise
    • Stock Market News UK Update: FTSE 100 & 250 Rise
    • DP Trading Room: Key Support Levels for the SPY
    • Stock Market News UK Update: FTSE 100 & 250 Rise
    • Stock Market News UK Update: FTSE 100 & 250 Rise

    Popular Posts

    • 1

      Polls show some good early signs for Kamala Harris

      July 26, 2024
    • 2

      Solana and Cardano: Solana is waiting for a new impulse

      July 18, 2024
    • 3

      The presidential race shifts — modestly, so far — toward Harris

      August 6, 2024
    • 4

      Donald Trump’s imaginary and frightening world

      September 23, 2024
    • 5

      DP Trading Room: PMO Sort on Earnings Darlings

      July 18, 2024

    Categories

    • Business (663)
    • Economy (965)
    • Politics (873)
    • Stocks (749)

    Disclaimer: therevenuerises.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 The Revenue Rises. All Rights Reserved.